HLA-A*0201 & B2M & NY-ESO-1 (SLLMWITQV)

NY-ESO-1, which is also well-known as New York esophageal squamous cell carcinoma 1, is an efficient target for cancer immunotherapy. This antigen is a member of cancer-testis antigens (CTAs) and is highly expressed in various cancers, including melanoma, ovarian, cervical cancer, etc. Adoptive T cell therapy with HLA-A2 restricted NY-ESO-1 transduced CD8+ T cells has improved the clinical response rates and overall survival of treatment-refractory melanoma patients. The Human HLA-A*0201 NY-ESO-1 complex protein is a complex of HLA-A*0201 of the MHC Class I, B2M and SLLMWITQV peptide of the NY-ESO-1.